Accessibility Menu
Nuwellis logo

Nuwellis(NASDAQ) NUWE

Market Cap$593.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-100%
1 Year-99%
1 Month-48%
$1.64
-4.09%
-0.07Today
After hours$1.64+$0.00 (+0.00%)
Nuwellis last closing stock price
MetricPriceDate
Last closeUSD 1.632026-08-06
Nuwellis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-63.37%USD 4.452026-07-30
1 month-48.25%USD 3.152026-07-07
3 month-95.73%USD 38.152026-05-08
Year to date-97.32%USD 60.902025-12-31
1 year-99.1%USD 182.002025-08-06
3 year-100%USD 120,393.002023-08-07
5 year-100%USD 21,917,700.002021-08-06
Since inception-100%USD 10,905,454,545.452012-02-16

Nuwellis Financials at a Glance

Market Cap

$593.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.77M

Net Income (TTM)

-$18.85M

EPS (TTM)

-$2,243.77

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.35 (Average)

Price

$1.64

Volume

12,934

Open

$1.70

Previous Close

$1.63

Daily Range

$1.62 - $1.80

52-Week Range

$1.34 - $235.20

Estimated Earnings Date

Aug 13, 2026

NUWE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nuwellis

Nuwellis makes medical devices that help remove excess fluid from patients. Its main systems support people with heart or kidney problems who do not respond to standard treatments. Hospitals use these devices to manage fluid overload in both adults and children.

Gadgets That Move Water: Products and Services

  • Aquadex FlexFlow System: Console, blood set, and catheter for fluid removal; 40% of 2025 revenue from pediatric use.
  • Aquadex SmartFlow System: Enhanced fluid management device for adults and children; used in critical care (32% of 2025 revenue).
  • Pediatric CRRT Device ("Vivian"): In development for small children (2.5–20 kg); not yet generating revenue.
  • Direct U.S. Sales: Devices sold to hospitals and clinics by in-house sales team; 97% of 2025 sales.
  • International Distribution: Specialty distributors in select countries; 3% of 2025 sales.

Growth Spurts and Strategic Moves

  • Exited most international markets in August 2025 to focus on U.S. growth.
  • Shifted manufacturing to KDI Precision Manufacturing in 2025 for efficiency.
  • Developed pediatric device "Vivian" with $3 million in NIH grants awarded since 2024.
  • Software upgrade for Aquadex planned for release in 2026.

What Makes Nuwellis Stand Out

Nuwellis focuses on fluid management for patients who do not respond to common drugs. Its devices allow precise fluid removal, especially for children and critical care patients. The company relies on a direct sales model in the U.S. and targets niche hospital markets.

Five Things You Need to Know

  • Net sales were $8.27 million in 2025, down 5.4% from 2024.
  • Pediatrics made up approximately 40% of 2025 revenue; critical care approximately 32%.
  • Gross margin was 62.0% in 2025, down from 64.9% in 2024.
  • Net loss was $17.52 million in 2025; ongoing operating losses since inception.

Bottom Line

Nuwellis has narrowed its focus to U.S. hospitals and pediatric care. The company faces ongoing losses but continues to develop specialized fluid management devices.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

38

CEO

John L. Erb

Website

www.nuwellis.com/patients

Headquarters

Eden Prairie, MN 55344, US

NUWE Financials

Key Financial Metrics (TTM)

Gross Margin

65.47%

Operating Margin

-141.53%

Net Income Margin

-214.90%

Return on Equity

-17015.80%

Return on Capital

-376.22%

Return on Assets

-262.98%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$593.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

364.30K

Volume

12.93K

Avg. Volume

2.90M

Financials (TTM)

Gross Profit

$5.74M

Operating Income

-$12.41M

EBITDA

-$7.80M

Operating Cash Flow

-$11.39M

Capital Expenditure

-$120.00K

Free Cash Flow

-$11.51M

Cash & ST Invst.

$2.08M

Total Debt

$265.00K

Nuwellis Performance Analysis

Nuwellis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,543,0007.9%
20232023-12-31USD 8,864,0003.8%
20242024-12-31USD 8,740,000-1.4%
20252025-12-31USD 8,270,000-5.4%
Nuwellis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-9.4%
Q32025-09-3028.5%
Q42025-12-319.3%
Q12026-03-31-0.9%
Nuwellis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4,294,892.18-70.7%
20232023-12-31USD -592,626.31-86.2%
20242024-12-31USD -11,766.63-98.0%
20252025-12-31USD -888.36-92.5%
Nuwellis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-8739.1%
Q32025-09-30100.9%
Q42025-12-31-367.9%
Q12026-03-31-39.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.40M

+26.2%

Gross Profit

$1.68M

+57.8%

Gross Margin

70.08%

N/A

Market Cap

$593.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$15.63K

N/A

Employees

38

N/A

Net Income

-$4.34M

-43.9%

EBITDA

-$4.30M

-46.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.08M

-18.5%

Total Debt

$265.00K

-46.1%

Accounts Receivable

$1.56M

+1.2%

Inventory

$1.78M

+1.5%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$265.00K

+9.1%

Return on Assets

-2.63%

N/A

Return on Invested Capital

-3.61%

N/A

Free Cash Flow

-$3.14M

-23.9%

Operating Cash Flow

-$3.11M

-22.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VINCVincerx Pharma, Inc.
$0.01+0.00%
BCTXWBriaCell Therapeutics Corp.
$0.00-0.00%
BACKIMAC Holdings, Inc.
$0.00+33.33%
ACONAclarion, Inc.
$2.35-0.42%

Trending Stocks

Symbol / CompanyPricePrice Chg
TTDThe Trade Desk
$17.67-0.07%
SPCXSpace Exploration Technologies
$114.92+0.06%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$26.93-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.03-0.01%

Questions About NUWE

What is the current price of Nuwellis?

Nuwellis is trading at $1.63 per share.

What is the 52-week range for Nuwellis?

Over the past 52 weeks, Nuwellis has traded between $1.34 and $235.20.

How much debt does Nuwellis have?

As of the most recent reporting period, Nuwellis reported total debt of $265.00K.

How much cash does Nuwellis have on hand?

Nuwellis reported $2.08M in cash and cash equivalents in its most recent financial results.

What is Nuwellis’s dividend yield?

Nuwellis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services